Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.

Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP, Lewis RA, Merkies ISJ, Sobue G, Durn B, Shebl A, van Schaik IN; PATH study group.

J Peripher Nerv Syst. 2019 Mar;24(1):72-79. doi: 10.1111/jns.12303. Epub 2019 Mar 1.

2.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.

van Schaik IN, van Geloven N, Bril V, Hartung HP, Lewis RA, Sobue G, Lawo JP, Mielke O, Cornblath DR, Merkies IS; PATH study group.

Trials. 2016 Jul 25;17(1):345. doi: 10.1186/s13063-016-1466-2.

3.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.

Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Tackenberg B, Mielke O; PRIMA Trial Investigators and the PATH Study Group.

J Peripher Nerv Syst. 2019 Mar;24(1):48-55. doi: 10.1111/jns.12302. Epub 2019 Feb 15.

4.

Immune Globulin Subcutaneous (Human) 20% (Hizentra®): A Review in Chronic Inflammatory Demyelinating Polyneuropathy.

Lamb YN, Syed YY, Dhillon S.

CNS Drugs. 2019 Aug;33(8):831-838. doi: 10.1007/s40263-019-00655-x. Review.

PMID:
31347096
5.

IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG.

Berger M, Harbo T, Cornblath DR, Mielke O.

Immunotherapy. 2018 Aug;10(11):919-933. doi: 10.2217/imt-2018-0036. Epub 2018 May 16. Review.

PMID:
29764262
6.

Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).

Léger JM, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Mielke O, Tackenberg B, Shebl A, Bauhofer A, Zenker O, Merkies IS; PRIMA study investigators.

J Peripher Nerv Syst. 2013 Jun;18(2):130-40. doi: 10.1111/jns5.12017.

7.
8.

Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.

Markvardsen LH, Sindrup SH, Christiansen I, Olsen NK, Jakobsen J, Andersen H; Danish CIDP and MMN Study Group.

Eur J Neurol. 2017 Feb;24(2):412-418. doi: 10.1111/ene.13218. Epub 2016 Dec 21.

PMID:
28000311
9.

A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.

Cornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA.

J Peripher Nerv Syst. 2018 Jun;23(2):108-114. doi: 10.1111/jns.12267. Epub 2018 Apr 26.

10.

Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.

Hartung HP, Mallick R, Bril V, Lewis RA, Sobue G, Lawo JP, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, van Schaik IN; PATH study group.

Eur J Neurol. 2019 Aug 10. doi: 10.1111/ene.14056. [Epub ahead of print]

PMID:
31400231
11.
12.
13.

Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement.

Kokubun N, Sada T, Yuki N, Okabe M, Hirata K.

Eur Neurol. 2013;70(1-2):65-9. doi: 10.1159/000350287. Epub 2013 Jun 19.

PMID:
23796651
14.

Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis.

Guptill JT, Runken MC, Eaddy M, Lunacsek O, Fuldeore RM.

Am Health Drug Benefits. 2019 May;12(3):127-135.

15.

Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.

Seino Y, Nakamura T, Hirohata M, Kawarabayashi T, Okushima T, Shoji M.

Intern Med. 2019 Mar 15;58(6):855-859. doi: 10.2169/internalmedicine.1723-18. Epub 2018 Nov 19.

16.

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.

van Doorn PA.

J Neurol Neurosurg Psychiatry. 1994 Nov;57 Suppl:38-42. Review.

17.

Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment.

Ellrichmann G, Gold R, Ayzenberg I, Yoon MS, Schneider-Gold C.

Ther Adv Neurol Disord. 2017 Feb;10(2):91-101. doi: 10.1177/1756285616679369. Epub 2016 Dec 9.

18.

Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.

Ritter C, Bobylev I, Lehmann HC.

J Neuroinflammation. 2015 Aug 14;12:148. doi: 10.1186/s12974-015-0361-1.

19.

Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.

Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, Antonini G, Fazio R, Gallia F, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Macchia R, Cavaletti G, Giannini F, Sabatelli M; IMC Trial Group.

Lancet Neurol. 2012 Jun;11(6):493-502. doi: 10.1016/S1474-4422(12)70093-5. Epub 2012 May 10.

PMID:
22578914
20.

Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US.

Guptill JT, Runken MC, Eaddy M, Lunacsek OE, Fuldeore RM, Blanchette CM, Zacherle E, Noone JM.

Patient Prefer Adherence. 2019 Apr 30;13:649-655. doi: 10.2147/PPA.S185852. eCollection 2019.

Supplemental Content

Support Center